Currently, phase III clinical trials of anti-PD-L1 antibodies in breast cancer patients are ongoing [10] and these antibodies are not approved by Food and Drug Administration (FDA) for metastatic breast cancer. This evidence concerns the gene CD274 and breast cancer.